Elite members get real-time data, technical charting, alerts, and no ads - starting at $24.96/mo.
Try Elite for Free
Last Close
16.78
Oct 22 • 3:59 PM ET Dollar change-0.15 Percentage change(-0.89%)
Aftermarket Close
16.78
Aftermarket • 4:15 PM ET Dollar change0.00 Percentage change(0.00%)
Index
-
Market Cap
1.05B
Enterprise Value
-
Income
-
Sales
-
Book/sh
-
Cash/sh
-
Employees
-
IPO
Jan 29, 2020
P/E
-
Forward P/E
-
PEG
-
P/S
-
P/B
-
P/C
-
P/FCF
-
EV/EBITDA
-
EV/Sales
-
Quick Ratio
-
Current Ratio
-
Debt/Eq
-
LT Debt/Eq
-
Option/Short
No / Yes
EPS (ttm)
-
EPS next Y
-
EPS next Q
-
EPS this Y
-
EPS next Y
-
EPS next 5Y
-
EPS past 3/5Y
- -
Sales past 3/5Y
- -
EPS Y/Y TTM
-
Sales Y/Y TTM
-
EPS Q/Q
-
Sales Q/Q
-
Earnings
-
EPS/Sales Surpr.
- -
Insider Own
-
Insider Trans
-
Inst Own
26.69%
Inst Trans
-
ROA
-
ROE
-
ROIC
-
Gross Margin
-
Oper. Margin
-
Profit Margin
-
SMA20
1.33%
SMA50
0.87%
SMA200
10.02%
Trades
Shs Outstand
62.50M
Shs Float
62.50M
52W High
17.25 -2.72%
52W Low
13.70 22.48%
Volatility
1.88% 1.64%
ATR (14)
0.29
RSI (14)
55.22
Beta
0.88
Rel Volume
1.18
Avg Volume
137.87K
Volume
163,226
Perf Week
1.88%
Perf Month
0.48%
Perf Quarter
9.60%
Perf Half Y
17.84%
Perf YTD
11.50%
Perf Year
11.57%
Perf 3Y
22.30%
Perf 5Y
-37.27%
Perf 10Y
-
Recom
-
Target Price
-
Prev Close
16.93
Price
16.78
Change %
-0.89%
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Fairbairn Robert WDirectorDec 18 '25Sale14.9810,294154,2040Dec 22 05:29 PM
Fairbairn Robert WDirectorDec 18 '25Sale14.9810,294154,2040Dec 22 05:29 PM
Fairbairn Robert WDirectorDec 19 '25Sale14.96060Dec 22 05:29 PM
Fairbairn Robert WDirectorDec 19 '25Sale14.96060Dec 22 05:29 PM
BlackRock Health Sciences Trust II's (BMEZ) investment objective is to provide total return and income through a combination of current income, current gains and long-term capital appreciation. The Trust seeks to achieve its investment objective by investing, under normal market conditions, at least 80% of its total assets in equity securities of companies principally engaged in the health sciences group of industries and equity derivatives with exposure to the health sciences group of industries. The Trust utilizes an option writing (selling) strategy in an effort to generate current gains from options premiums and to enhance the Trust's risk-adjusted returns.
Portfolio ManagerDr. Xiang Liu Ph.D.